ASCO 2026: Immatics is presenting data on its second generation PRAME targeting cell therapy in gynecological cancers and synovial sarcoma
CEO Harpreet Singh walks us though the data and reminds us how this second generation approach uses CD4+ helper T-cells in addition to CD8 for additional firepower.









.png)